Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP 2: Semaglutide 2.4 mg in Overweight/Obesity with Type 2 Diabetes
NCT03552757Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in Body Weight (%) at 68 weeks and Participants Who Achieve Body Weight Reduction >= 5% at 68 weeks. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03552757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552757.